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Abstract
Background: Neutrophils play a major role in inflammation by releasing large amounts of ROS produced by NADPH-oxidase
and myeloperoxidase (MPO). The proinflammatory cytokine TNFa primes ROS production through phosphorylation of the
NADPH-oxidase subunit p47phox on Ser345. Conventional anti-inflammatory therapies remain partially successful and may
have side effects. Therefore, regulation of neutrophil activation by natural dietary components represents an alternative
therapeutic strategy in inflammatory diseases such as inflammatory bowel diseases. The aim of this study was to assess the
effect of punicic acid, a conjugated linolenic fatty acid from pomegranate seed oil on TNFa-induced neutrophil
hyperactivation in vitro and on colon inflammation in vivo.
Methodology and Principal Findings: We analyzed the effect of punicic acid on TNFa-induced neutrophil upregulation of
ROS production in vitro and on TNBS-induced rat colon inflammation. Results show that punicic acid inhibited TNFa-
induced priming of ROS production in vitro while preserving formyl-methionyl-leucyl-phenylalanine (fMLP)-induced
response. This effect was mediated by the inhibition of Ser345-p47phox phosphorylation and upstream kinase p38MAPK.
Punicic acid also inhibited fMLP- and TNFa+fMLP-induced MPO extracellular release from neutrophils. In vivo experiments
showed that punicic acid and pomegranate seed oil intake decreased neutrophil-activation and ROS/MPO-mediated tissue
damage as measured by F2-isoprostane release and protected rats from TNBS-induced colon inflammation.
Conclusions/Significance: These data show that punicic acid exerts a potent anti-inflammatory effect through inhibition of
TNFa-induced priming of NADPH oxidase by targeting the p38MAPKinase/Ser345-p47phox-axis and MPO release. This
natural dietary compound may provide a novel alternative therapeutic strategy in inflammatory diseases such as
inflammatory bowel diseases.
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Introduction
Inflammatory disorders such as inflammatory bowel diseases
(IBD), rheumatoid arthritis, atherosclerosis, metabolic syndrome
and ischemia/reperfusion injury are recognized as a major health
problem worldwide [1,2]. One common characteristic of these
diseases is excessive production of pro-inflammatory mediators
such as TNFa, GM-CSF, IL-1, IL-6, IL-8, leukotriene B4 and
PAF, the presence of highly activated inflammatory cells such as
neutrophils, monocytes and macrophages and excessive produc-
tion of reactive oxygen species (ROS) [2–6].
Polymorphonuclear neutrophils play a key role in host defenses
against invading microorganisms and excessive neutrophil activation
participates to tissue damage in inflammatory disorders [5–9]. In
response to a variety of agents, they migrate to the inflammatory site
where they release proteases, bactericidal peptides and large quantities
of ROS, a process known as the respiratory burst [9]. A major source
of ROS in inflammatory lesions comes from the reduction of oxygen to
t h es u p e r o x i d ea n i o n( O 2
2)b yn e u t r o p h i lN A D P Ho x i d a s e ,a
multicomponent enzyme system [10] and by myeloperoxydase
(MPO) which produces hypochlorica c i df r o mh y d r o g e np e r o x i d e
[7]. In resting cells NADPH oxidase is inactive and its components are
distributed between the cytosol and membranes. When cells are
activated, the cytosolic components (p47phox, p67phox, p40phox and
Rac2) migrate to the membranes and associate with gp91phox/NOX2
and p22phox which form the flavocytochrome b558 to assemble the
catalytically active oxidase [10–13]. P47phox phosphorylation on
several serines plays a pivotal role in oxidase activation in intact cells
[14–16].Neutrophil superoxide production can be potentiated by prior
exposure to ‘‘priming’’ agents such as the pro-inflammatory cytokines
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6458TNFa, GM-CSF and IL-8 [17,18]. These cytokines inherently induce
a very weak oxidative response by neutrophils, but they strongly
enhance neutrophil release of ROS upon exposure to a secondary
applied stimulus such as bacterial N-formyl-methionyl-leucyl-phenyl-
alanine (fMLP) [17–23]. Priming of neutrophils is an important process
in inflammatory diseases since it participates to tissue injury involved in
inflammation [17]. In healthy subjects, the activation of NADPH
oxidase of neutrophils is tightly regulated to avoid tissue damage. We
have recently found that phosphorylation of p47phox on Ser345
represents a critical mechanism for TNFa-induced priming of ROS
production by neutrophils as shown by site-directed mutagenesis of
Ser345 and use of a competitive inhibitory peptide containing the
Ser345 sequence [18]. This peptide inhibited TNFa-induced priming
of ROS production while preserving the physiological response to
bacterial derived N-formyl peptides. The phosphorylation of this site is
controlled by p38MAPKinase in TNFa-primed neutrophils. We have
shown that this regulation can be impaired in chronic inflammatory
states whereby neutrophils isolated from synovial fluids of rheumatoid
arthritis patients are primed and are prone to release high amounts of
ROS [18]. In agreement, their p47phox cytosolic subunit of NADPH
oxidase wasfound to be phosphorylated on Ser345and the competitive
peptide decreased ROS hyperproduction by neutrophils [18].
Inflammatory bowel diseases (IBD) are systemic inflammatory
disorders most commonly targeting gastrointestinal tract [24]. Such
disease states as ulcerative colitis, Crohn’s disease and infectious
enterocolitis, involve neutrophil migration across intestinal epithe-
lia, neutrophil accumulation in the inflamed intestine [24,25],
overproduction of inflammatory cytokines, and release of massive
amounts of ROS from neutrophils [26,27]. Both excessive
production of ROS and release of degradative enzymes by
neutrophils have been implicated in IBD [26,27]. Therefore
decreasing p47phox phosphorylation on Ser345 and subsequent
ROS hyperproduction by neutrophils without altering neutrophil
normal response to bacterial products, would represent a novel and
safe strategy to develop new therapeutic anti-inflammatory agents.
Since conventional existing therapies against IBD remain
partially successful, and often result in significant side effects for
patients, novel and safer methods, including dietary manipulations,
have been used as an alternative therapeutic or prevention strategy
in IBD and other inflammatory diseases which involve PMN
activation and oxidative stress. For example, dietary n-3 polyun-
saturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), naturally present in fish oils have
beenwidely used in animal models and in human clinical trials [28].
They have been shown to attenuate clinical signs of inflammation
and neutrophil infiltration into inflamed tissues in an experimental
model of colitis [29]. In presence of aspirin, n-3 PUFA are
converted to active substances named resolvins and protectins
which play a pivotal role in the resolution of inflammation [29].
However, the effects of n-3 PUFA on neutrophil functions remain
controversial, depending on the doses supplemented and the
experimental model used [30–33]. Recently, fatty acids with
conjugated double bonds like conjugated linoleic acid (CLA) and
conjugated linolenic acid (ClnA) have attracted considerable
attention because of their suggested health benefits on inflammation
and some cancers [34–37]. These conjugated fatty acids have been
reported to reduce the incidence of mammalian tumors in mice, to
inhibit proliferation and invasion of cancer cells in culture and to
promote apoptosis of cancer cells [38,39]. In western countries,
CLAandClnA arepresentonlyas tracefattyacids indietaryfats. In
other countries around the Mediterranean sea, Iran, Afghanistan,
India, China, and Japan, plants such as pomegranate (Punica
granatum, Punicaceae), bitter gourds (Momocardia charantia), and other
cucurbitacae, which contain high amounts of punicic acid a ClnA
isomer (9Z,11E,13Z) containing cis-9, trans-11, cis-13 double bonds
in the C18 carbon chain, are regularly consumed [34,35]. One
might speculate that intake of these specific conjugated fatty acids
could account for the lower incidence of inflammatory diseases in
these populations [40,41].
T h ea i m so ft h i ss t u d yw e r et oi n v e s t igate the effects of punicic acid
on TNFa-induced ROS over-production by human neutrophils and
to evaluate the effect of punicic acid in a rat model of 2, 4, 6-
trinitrobenzenesulfonic acid (TNBS)-induced colitis. We found that
punicic acid exerted a strong inhibitory effect on TNFa-induced
priming of ROS production by neutrophils in vitro, through the
inhibition of p47phox phosphorylation on the priming site Ser345
and the upstream kinase p38MAPK. Furthermore, oral administra-
tion of pure punicic acid, or pomegranate seed oil rich in punicic acid
to rats prevented TNBS-induced colitis and lowered ROS-induced
tissue damage. Punicic acid may have beneficial anti-inflammatory
effects by down regulating neutrophil hyper-activation.
Results
Punicic acid inhibits TNFa-induced ROS overproduction
by human neutrophils while preserving the bacterial N-
formyl peptides beneficial functions
We first tested the effect of punicic acid on TNFa-induced
neutrophil priming of ROS production in response to fMLP.
Neutrophils were incubated in the presence or absence of 10 mM
of punicic acid for 30 min, treated in the presence or absence of
TNFa, stimulated by fMLP and ROS production measured by
luminol-amplified chemiluminescence. Our results show that in
resting conditions and in the presence of TNFa alone, neutrophils
produced a basal low level of ROS and punicic acid had no
inhibitory effect on this process (Figure 1A and 1C). The
addition of fMLP resulted in the stimulation of ROS production,
and as expected TNFa induced priming of fMLP-induced ROS
production ; treatment of neutrophils with punicic acid prior to the
addition of TNFa resulted in the inhibition of the priming effect of
TNFa without altering the response induced by fMLP (Figure 1B
and Figure 1C). The effect of punicic acid was dose dependent
starting from 10 mMu pt o4 0mM in final concentration (Figure
D). Punicic acid did not inhibit PMA-induced ROS production by
neutrophils (Figure 1E), suggesting that punicic acid did not
inhibit NADPH oxidase activity nor scavenged ROS. At these
concentrations punicic acid did not affect PMN viability as
determined by the trypan blue exclusion method (data not shown).
These results clearly show that punicic acid inhibited TNFa-
induced ROS hyperproduction by neutrophils without affecting
fMLP- nor PMA-induced responses.
We have also tested the effect of other fatty acids commonly
found in edible oils such as linoleic acid (18 :2 v 6), a linolenic acid
(18:3 v 3) and a conjugated linoleic acid (cis 9, 11 trans) compared
to punicic acid. Results show (Figure 1F) that none of the tested
fatty acids had an inhibitory effect on TNFa-induced priming of
ROS production by neutrophils compared to punicic acid.
Punicic acid inhibits TNFa-induced p47phox
phosphorylation on Ser345 and p38MAPkinase
phosphorylation
Priming of neutrophil ROS production by the pro-inflamma-
tory cytokine TNFa is mediated by the phosphorylation of
p47phox on Ser345 [18]. We then analysed the effect of punicic
acid on this process using a specific antibody directed against this
phosphorylated site. Results show that punicic acid inhibited
TNFa-induced p47phox phosphorylation on Ser345 in a dose-
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antibody directed against non phosphorylated p47phox showed
that the same amount of proteins was present for all conditions
tested. Phosphorylated and total p47phox from several experi-
ments were quantified by densitometry and the amount of
phosphorylated p47phox corrected for the amount of p47phox.
Figure 1. Punicic acid (PA) inhibits TNFa-induced ROS over-production by human neutrophils. (A) Human neutrophils (5610
5 cells in 0.5 ml
Hanks buffer) were incubated in the absenceor the presenceof PA (10 mM) for 30 min; TNFa (10 ng/ml) was added and ROS production was measured by
chemiluminescencetechniqueinthepresenceof10 mM luminol. (B) Human neutrophils (5610
5cells in0.5 mlHanksbuffer) wereincubatedintheabsence
orthepresenceofPA (10 mM) for 30 min; TNFa (10 ng/ml) wasaddedfor20 min beforestimulation withfMLP(10
27 M). ROSproductionwasmeasuredby
chemiluminescence technique in the presence of 10 mM luminol. (C) Total chemiluminescence in each condition was quantified and presented as mean+/
2SEM of 6 experiments (PA 10 mM), (* p,0.05 with versus without PA). (D) Dose effect of PA on TNFa-primed cells. Mean+/2S E Mo f6e x p e r i m e n t so ft h e
doseeffectofPA,*p,0.05ascomparedtoTNFa+fMLPcontrols(100%).(E)DoseeffectofPAonPMA(100 ng/ml)-inducedneutrophilROSproduction.One
representative of four experiments. (F) Human neutrophils (5610
5 cells in 0.5 ml Hanks buffer) were incubated in the absence or the presence of 10 mMo f
linoleic acid (LA), linolenic acid (LnA), conjugated linoleic acid (CLA) or PA for 30 min; TNFa (10 ng/ml) was added for 20 min before stimulation with fMLP
(10
27 M). ROS production was measured by chemiluminescence technique in the presence of 10 mM luminol. Total chemiluminescence in each condition
was quantified and presented as mean+/2SEM of 6 experiments, * p,0.05 as compared to TNFa+fMLP (control 100%).
doi:10.1371/journal.pone.0006458.g001
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TNFa-induced p47phox phosphorylation starting from 10 mM
concentration as compared to TNFa alone (Figure 2B). The
phosphorylation of p47phox on Ser345 is mediated by p38MAPK
in TNFa-primed neutrophils (18). We therefore tested the effect of
punicic acid on TNFa-induced p38MAPK phosphorylation.
Results show that punicic acid inhibited p38MAPK phosphory-
lation paralleling the inhibition of p47phox phosphorylation on
Ser345 with almost no detectable Phospho-Ser345 and phospho-
P38MAPK at 20 mM punicic acid (Figure 2C and 2D). These
results suggest that punicic acid inhibited TNFa-induced priming
of ROS production by neutrophil NADPH oxidase by targeting
the p38MAPKinase/Ser345-p47phox-axis.
Punicic acid Inhibits TNFa- and fMLP -induced MPO
release from neutrophils
Superoxide anion (O2
2) produced by NADPH oxidase is the
source of other ROS generated by neutrophils. O2
2.is transformed
into H2O2 by spontaneous dismutation at acidic pH in the
phagosome or in the extracellular medium. Myeloperoxidase
(MPO) released from azurophilic granules catalyses the transfor-
mation of H2O2 in the presence of a halogen (Cl
2,Br
2,I
2) into
highly toxic molecules such as hypochloric acid (HOCl). Other
reactions between OCl
2 and H2O2 can lead to the formation of
singlet oxygen (
1O2). Most of the hypochloric acid thus generated
is converted into toxic chloramines. Thus NADPH oxidase
activation and MPO degranulation act in synergy during the
inflammatory process. To test whether punicic acid could also
affect neutrophil degranulation, human neutrophils were treated
or not with punicic acid and MPO release was assessed by
measuring its activity. As shown in Figure 3, TNFa alone did not
induce MPO release in agreement with the literature (42), however
it enhanced fMLP-induced degranulation. Cytochalasin B used as
a positive control also enhanced fMLP-induced degranulation.
Punicic acid inhibited fMLP and TNFa+fMLP- and cytochalasin
B+fMLP-induced degranulation of azurophilic granules, resulting
in less MPO release by neutrophils. Punicic acid had no direct
effect on MPO enzymatic activity (data not shown). Taken
together these results indicate that punicic acid inhibited TNFa-
priming of both neutrophil NADPH oxidase activation and MPO
release, and thus it may have an anti-inflammatory activity.
Punicic acid inhibits TNFa-induced priming of ROS
production by rat neutrophils and protects rats from
TNBS-induced colon inflammation
Neutrophils and TNFa are two major elements known to be
involved in inflammatory bowel diseases (IBD) and excessive
production of ROS and release of degradative enzymes by
neutrophils have been implicated in IBD [26,27]. The results
described above suggest that punicic acid could have anti-
Figure 2. Punicic acid inhibits TNFa-induced p47phox phosphorylation on Ser345 and p38MAPKinase phosphorylation. (A)
Neutrophils (1610
7 cells/ml) were pretreated with increasing concentrations of punicic acid (10 to 40 mM) for 30 minutes, then incubated with TNFa
(10 ng/ml) or without (control) for 20 minutes. Cells were then lysed and proteins from 7610
5 cells were analyzed with SDS-PAGE and
immunoblotting with anti-phospho-ser345 antibody (pSer345) or anti-p47phox antibody (p47phox). (B) Western blots from different experiments
were scanned ; phosphorylated and total p47phox were quantified by densitometry , and the intensity of phosphorylated p47phox was corrected for
the amount of p47phox. Results are expressed as mean+/2SEM (n=3), * p,0.05 as compared to TNFa alone. (C) Neutrophils (1610
7 cells/ml) were
pretreated with increasing concentrations (0, 10, 20 mM) of punicic acid for 30 minutes, then incubated with or without TNFa (10 ng/ml) for 20
minutes. Cells were then lysed and proteins from 7610
5 cells were analyzed with SDS-PAGE and immunoblotting with anti-phospho-ser345 antibody
(pSer345), anti phospho p-38 MAPK (P-P38MAPK) and anti-p47phox antibody (p47phox). (D) Western blots from different samples treated or not with
TNFa with or without 20 mM punicic acid were scanned, phosphorylated p38MAPK and total p47phox were quantified by densitometry and the
intensity of phosphorylated p38-MAPK was corrected for the amount of p47phox. Data are representative of 3 independent experiments using cells
from different healthy donors. Results are expressed as mean+/2SEM (n=3). * p,0.05 as compared to TNFa alone.
doi:10.1371/journal.pone.0006458.g002
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punicic acid in an animal model of inflammatory bowel diseases.
Studies have shown that among animal models of intestinal
inflammation, TNBS induces macroscopic and histological
features in rats or mice, similar to those occurring in human
IBD and characterized by the presence of high number of
activated neutrophils [43].
In order to validate the model, we first tested the effect of
punicic acid on TNFa-induced priming of ROS production by rat
neutrophils. Rat neutrophils were incubated in the presence or
absence of 10 mM of punicic acid for 30 min, treated in the
presence or absence of rat TNFa then stimulated by fMLP. ROS
production was then measured by luminol-amplified chemilumi-
nescence. As expected, results show that TNFa alone and fMLP
alone, induced low level of ROS production, and punicic acid had
only a moderate inhibitory effect on this process (Figure 4A, 4B
and 4C). However, treatment of rat neutrophils by TNFa and
their subsequent stimulation with fMLP resulted in enhanced
ROS production. Treatment of neutrophils with punicic acid prior
to the addition of TNFa resulted in the inhibition of ROS
production by rat neutrophils (Figure 4B and 4C), suggesting
that punicic acid inhibited the priming effect of TNFa.W e
secondly, showed that TNFa induced phosphorylation of p47phox
on Ser345 in rat neutrophils and punicic acid inhibited this process
(data not shown). These results suggest that, as observed in human
neutrophils, punicic acid inhibited TNFa-induced priming of
ROS production by targeting the p38MAPKinase/Ser345-
p47phox-axis in rat neutrophils.
We then used a rat model challenged with TNBS to examine
whether dietary supplementation with punicic acid would prevent
intestinal inflammation. In this model, TNBS was administered
intra-rectally to induce an immunological response similar to the
one found in human Crohn’s disease [44]. Rats were daily
gavaged with free punicic acid or PBS during 10 days before
TNBS treatment. Figure 5A depicts a representative section of
colon from untreated rats, while Figure 5B depicts a represen-
tative section of colon from rats 48 h after TNBS administration.
As shown in these figures, the colon from TNBS-treated versus
vehicle-treated rats displayed an extensive ulceration with cellular
necrosis, oedema and inflammatory infiltrate. Colons from rats
gavaged with punicic acid and treated with TNBS were
characterized by a moderate inflammatory infiltrate with only
punctuate mucosal erosion, indicating an important reduction of
damage to the colon (Figure 5C). The representative histological
features encountered for TNBS and punicic acid-TNBS treated
rats were examined by two independent pathologists. As shown in
Figure 5D and 5E, punicic acid induced a significant
improvement in the macroscopic and histological scores evaluated
according to the multi-parametric Wallace and Ameho criteria.
To identify if the protective effect of punicic acid was due to its
inhibitory action on neutrophil excessive activation, we analyzed in
vivo neutrophil priming in colon sections by confocal microscopy
using the anti-phosphoSer345-antibody. NOX2 antibody was
used to detect total phagocytic NADPH oxidase. Confocal analysis
clearly showed (Figure 6) that control untreated rat colon
(Figure 6-PBS) expressed low NOX2 and phospho-Ser345 (p-
Ser345) fluorescence intensity in accordance with few neutrophil
infiltration while TNBS treatment induced bright NOX2 and p-
Ser345 fluorescence intensity in accordance with massive neutro-
phil infiltration and priming or activation as assessed by the
colocalization of anti-gp91phox/NOX2 and the anti-phospho-
Ser345-antibodies, respectively (Figure 6, p-Ser345, NOX2,
Merge). Punicic acid significantly reduced neutrophil infiltration
and priming/activation in the colon of TNBS-treated rats, as
shown by decreased NOX2 and p-Ser345 fluorescence intensity
compared to TNBS-treated rats that did not receive punicic acid.
Neutrophil hyper-activation often results in excessive ROS
production and degranulation which release high amounts of
enzymes such as MPO resulting in lipid peroxidation and tissue
injury. In this study, we measured MPO activity and F2-
isoprostane the most reliable in vivo lipid peroxidation marker
[45], in colons of control and punicic acid/TNBS challenged rats.
Figure 7A and 7B show that TNBS induced a concomitant
increase in MPO activity and F2-isoprostane production, as
compared to control rats receiving only vehicle (PBS). Oral intake
of punicic acid significantly decreased both MPO and F2-
isoprostane levels. These data suggest that punicic acid has an
anti-inflammatory effect through neutrophil inhibition of MPO
and ROS release resulting in a decrease in lipid peroxidation and
tissue injury.
Pomegranate seed oil intake protects rats from TNBS-
induced colon inflammation
Pomegranate seed oil is a natural source of punicic acid which
comprise 80% of its total fatty acid content [46], we therefore
evaluated if dietary supplementation of this oil has the same
protective effect on TNBS-induced inflammation as pure punicic
acid. It has been reported that pomegranate seed oil is efficient in
vivo when it is used between 1% and 5% by weight of diet for a
period of 3 to 32 weeks (39,46). We thus used a dose of 2%
pomegranate seed oil by weight of diet for 10 days in our study. For
this purpose, rats were daily gavaged with 0.5 ml of pomegranate
seed oil for 10 days before TNBS treatment. Figure 8A depicts a
representativesectionofcolonfromuntreatedrats,whileFigure8B
depicts a representative section of colon from rats 48 h after TNBS
administration. As shown in these figures, the colon from TNBS-
treated versus vehicle-treated rats displayed an extensive ulceration
with cellular necrosis, oedema and inflammatory infiltrate. Colons
from rats gavaged with pomegranate seed oil and treated with
TNBS were characterized by a moderate inflammatory infiltrate
with only punctuate mucosal erosion, indicating an important
reduction of damage to the colon (Figure 8C). The representative
Figure 3. Effect of punicic acid on neutrophil degranulation.
Human neutrophils from healthy donors were pretreated (open bars) or
not (black bars) with punicic acid for 30 min, challenged with TNFa or
cytochalasin B, then stimulated with fMLP for 3 min. Cells were
centrifuged and MPO activity was determined in the supernatants using
H2O2 and TMB as described in Materials and Methods. MPO activity was
expressed in MU/min relative to a standard curve established with a
known number of neutrophils. Data are representative of 4 different
experiments. * P,0.05 vs untreated cells.
doi:10.1371/journal.pone.0006458.g003
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oil-TNBS treated rats were examined by two independent
pathologists. As shown in Figure 8D and 8E, pomegranate seed
oil induced a significantly improvement in the macroscopic and
histological scores evaluated according to the multi-parametric
Wallace and Ameho criteria. Taken together, our results provide
evidence that punicicacid/orpomegranate seed oilcould haveanti-
inflammatory effect and may have a promising protective effect
against inflammatory related diseases.
Discussion
In the present study we show that punicic acid, a conjugated fatty
acid, is a strong inhibitor of TNFa-induced priming of ROS
production and MPO release by neutrophils. The inhibition of
TNFa-induced priming of NADPH oxidase is the result of the
inhibition of the phosphorylation of p38MAPKinase and p47phox on
Ser345. The results also show that pure punicic acid and pomegranate
seed oil protected rats from TNBS-induced colon inflammation. This
protection could be the result of the inhibition of ROS/MPO-induced
tissue damage as shown by the reduced level of lipid peroxidation
product F2-isoprostane. We conclude that punicic acid could exert
potent anti-inflammatory effects through: 1) the inhibition of TNFa-
induced p38MAPK and p47phox-Ser345 phosphorylation in neutro-
phils, resulting in the inhibition of ROS excessive release and 2) the
inhibition of MPO release, thus resulting in low tissue damage. This
natural dietary compound may provide a novel alternative therapeutic
strategy for inflammatory diseases which involve oxidative stress such
as IBD, rheumatoid arthritis and atherosclerosis.
Proinflammatory cytokines play a key role in the pathophysiology
of IBD [47] and anti-TNFa antibodies are therapeutically used in
some severe forms of IBD [48]. TNFa is involved in priming of
neutrophil ROS production which is a key process in inflammatory
reaction (17). The presence of primed neutrophils was described in
various inflammatory diseases such as rheumatoid arthritis, IBD,
coronary heart disease and diabetes [18,49,50]. One of the
molecular mechanism underlying this priming state of neutrophil-
ROS production is the phosphorylation of p47phox on Ser345. A
potential anti-inflammatorytherapeuticintervention would be to use
nutritional agents to decrease the phosphorylation of this site and
subsequent ROS overproduction in inflammatory diseases without
altering normal ROS production which is necessary for innate
Figure 4. Punicic acid (PA) inhibits TNFa-induced ROS over-production by rat neutrophils. (A) Rat neutrophils (5610
5 cells in 0.5 ml
Hanks buffer) were incubated in the absence or the presence of PA (10 mM) for 30 min; TNFa (10 ng/ml) was added and ROS production was
measured by chemiluminescence technique in the presence of 10 mM luminol. (B) Rat neutrophils (5610
5 cells in 0.5 ml Hanks buffer) were incubated
in the absence or the presence of PA (10 mM) for 30 min; rat TNFa (10 ng/ml) was added for 20 min before stimulation with fMLP (10
27 M). ROS
production was measured by chemiluminescence technique in the presence of 10 mM luminol. (C) Total chemiluminescence in each condition was
quantified and presented as mean+/2SEM of 3 experiments (PA 10 mM). * P,0.05 treated vs untreated cells.
doi:10.1371/journal.pone.0006458.g004
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punicic acid, a naturally occurring fatty acid present in the diet of
humans,was ableto inhibitTNFa-induced priming state and reduce
ROS production by human neutrophils without affecting ROS
production induced by the bacterial chemotactic peptide fMLP or
the PKC activator PMA. This inhibitory effect was mediated by the
inhibition of p47phox phosphorylation on Ser345 and the
phosphorylation of the upstream kinase p38MAPK. Therefore,
punicicacid didnotinhibitNADPH oxidaseactivity itself,but rather
exerted an anti-priming effect by preventing excessive NADPH
oxidase activation and subsequent ROS derived oxidative stress.
This is the first natural compound known to reduce TNFa-induced
phosphorylation of Ser345-p47phox and the priming process.
We also showed that punicic acid inhibited MPO degranulation
by neutrophils. As the presence of MPO and ROS (especially
H2O2) at the inflammatory site generates toxic molecules, the
inhibitory effect of punicic acid on MPO degranulation further
support the potential action of this compound as an anti-
inflammatory agent. The mechanisms of this inhibition are not
known and will be the subject of further investigation in our
laboratory. However in vitro studies showed that punicic acid had
no effect on fMLP-induced migration of neutrophils (data not
shown), suggesting that it could inhibit neutrophil toxic activities
without affecting its beneficial functions required for host defense.
Other fatty acids have different effects on neutrophil ROS
production. Linoleic acid, which is the major fatty acid consumed
in western countries, has been shown to act synergistically with
TNFa to activate neutrophil ROS production [51]. Linoleic acid
long chain derivative, arachidonic acid can activate directly
neutrophils [52] and can be enzymatically converted into pro-
inflammatory eicosanoids such as LTB4, and PGE2 [53–55],
which are chemo-attractants and strong activators of neutrophils.
In contrast, long chain n-3 PUFA, such as EPA and DHA, mainly
provided by fish oil, are converted to less inflammatory eicosanoids
and have been reported to counteract the harmfull effects of n-6
PUFA eicosanoids [28]. Hardy et al demonstrated that pre-
treating neutrophils with arachidonic acid, EPA and DHA
enhanced their response to either fMLP, or PMA, thereby
producing more superoxide than when challenged with the
stimulators only [56]. Li et al reported that EPA and DHA
caused augmented responses in TNFa-primed neutrophils [57].
However, none of these in vitro and in vivo experiments have
investigated the molecular mechanism underlying this augmented
ROS production. Studies have suggested that conjugated linoleic
acid induced activation of PPAR gamma and delta and protected
from experimental inflammatory bowel disease [58] ; however the
effect of punicic acid on this mechanism is not known.
To test if punicic acid could have anti-inflammatory effect in vivo,
we tested its effect in TNBS-induced inflammation, a well known
model ofbowel inflammation [59].There isample experimental and
clinical evidence to suggest that the inflamed colon undergoes
substantial oxidative stress by neutrophil derived oxidants [27],
Figure 5. Effects of punicic acid on TNBS-induced colitis. Rats were gavaged with punicic acid (PA) dissolved in PBS (400 mg/0.5 ml) or PBS
alone (0.5 ml) once a day for 10 days before the initiation of TNBS treatment. For the induction of colitis, rats were anesthetized, then they received
an intrarectal administration of TNBS (250 ml, 150 mg/Kg) dissolved in 50% ethanol in 0.9% NaCl. Control rats received the vehicle ethanol or a saline
solution using the same technique as described previously. Animals were sacrificed 2 days after TNBS administration. Macroscopic and histological
analysis of colons were evaluated blindly by two investigators. Photomicrographs (magnification 640) are representative of H&E stained slides of
paraffin embedded colonic tissues recovered from (A) controls, (B) TNBS alone and (C) TNBS plus PA . Histologic and macroscopic lesions following
TNBS treatment are represented by Wallace score (D) and Ameho score (E) as described in Materials and methods. The tissues are representative of 8
rats from each experimental group (* p,0.01 between TNBS and PA+TNBS).
doi:10.1371/journal.pone.0006458.g005
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chronic intestinal inflammation. The results presented in this study
show for the first time the presence of primed neutrophils in the
inflamed colon as detected by the anti phosphoSer345-p47phox
antibody. Consistent with the marked mucosal ROS induced injury,
rats treated with TNBS had significantly elevated levels of the lipid
peroxidation product F2-isoprostane compared with controls.
Punicic acid or pomegranate seed oil intake protected from
TNBS-induced inflammation probably by inhibiting neutrophil
priming and ROS-induced reactions. Punicic acid also inhibited
neutrophilrecruitment inthismodel.SinceTNFa isnot chemotactic
forneutrophilsandpunicicacidaffected moderatelyIL-8 and fMLP-
induced neutrophil migration, the effect of punicic acid on
neutrophil recruitment in vivo could be indirect. One possible
explanation is that since TNFa-induced ROS production is known
to control chemokine production via oxidant-dependent factors [60–
62], punicic acid by inhibiting TNFa-induced excessive ROS
production could inhibit ROS-mediated inflammatory reactions.
Since punicic acid is a major fatty acid of pomegranate seed oil,
representing 60 to 80% of total fatty acids [46], we decided to use
a dietary pomegranate seed oil as a supplement to rats, instead of
pure punicic acid. In vivo studies indicated that given to rats in the
triglyceride form, punicic acid was well absorbed, metabolized and
stored in rat tissues [39,46,63,64]. Pomegranate seed oil provided
protection against TNBS-induced ulcerations and tissue damage.
This protective effect of pomegranate seed oil could be attributed
to punicic acid the major fatty acid of this oil which is in good
agreement with our results obtained with pure punicic acid used as
free fatty acid. However, it cannot be excluded that unknown
minor compounds found in pomegranate seed oil could have some
effects in vivo. Since, pomegranate seed oil provided protection
against TNBS-induced inflammation; therefore, dietary intake of
this oil could be protective for inflammatory diseases.
In humans, high amounts of EPA and DHA have been used to
prevent inflammatory complications of various diseases and to
reduce circulating levels of inflammatory markers [28]. There are
Figure 6. Punicic acid inhibits the phosphorylation of p47phox on Ser345 in vivo. Rats received punicic acid dissolved in PBS (400 mg/
0.5 ml) or PBS alone (0.5 ml) once a day for 10 days before TNBS treatment. Rats were anesthetized, then they received an intrarectal administration
of TNBS (250 ml, 150 mg/Kg) dissolved in 50% ethanol in 0.9% NaCl . Control rats received only 50% ethanol vehicle. Animals were sacrificed 2 days
after TNBS administration. Colons were fixed in formalin and paraffin-embedded tissue sections (5 mm) and were analyzed by confocal microscopy as
indicated in the Methods section. The tissues were incubated overnight at 4uC with rabbit anti-phospho-Ser345p47phox polyclonal antibody
(1:1000), and mouse anti-gp91phox monoclonal antibody (1:1000) diluted in 1% BSA/PBS. Following this incubation, the tissues were washed four
times in PBS and incubated with Alexa Fluor 488-(green) conjugated goat anti-rabbit antibody (1:200) diluted in 1% BSA/PBS and Alexa Fluor 568
(red) conjugated goat anti mouse (1:200) for 1 h at room temperature in the dark. Stained cells were examined with a 63/1.4 numerical aperture
objective under a Zeiss LSM510 confocal microscope and the images were imported into an LSM image browser for analysis. Merge corresponds to
colocalisation of NOX2 and P-Ser345 as described in materials and methods.
doi:10.1371/journal.pone.0006458.g006
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diet supplementation or manipulation with fish oils in IBD and RA
[65] This may be due to the above described priming effect of
these n-3 PUFA, which may minimize their inhibitory effect on
arachidonic acid derived eicosanoid production.
In conclusion, this study shows that punicic acid in vitro inhibited
TNFa-induced priming of neutrophil ROS production by
targeting the p38MAPKinase/p47phox/NADPH oxidase axis
and inhibited MPO release in the extracellular media. Further-
more, punicic acid and punicic acid rich pomegranate seed oil
have an in vivo anti-inflammatory effect by limiting neutrophil
activation and lipid peroxidation consequences. Punicic acid and
pomegranate seed oil would be highly protective against
inflammation and could be used for the prevention and treatment
of various inflammatory diseases, such as inflammatory bowel
disease, rheumatoid arthritis and coronary heart disease.
Materials and Methods
Reagents and antibodies
Punic acid was purchased from Larodan (Malmo ¨, Sweden).
Pomegranate seed oil was purchased from All organic trading
(GmbH, Kempten, Germany). TNFa was from R&D Systems.
TNBS, fMLP, PMA, protease and phosphatase inhibitors were
from Sigma Chemical Co. Injection-grade water and 0.9% NaCl
were endotoxin-free in the limulus test (Charles River). Endotoxin-
free buffers and salt solutions were from Invitrogen. Anti phospho-
Ser345-p47phox and anti-p47phox were previously described
[18]. Anti phospho-p38MAPKinase was from Cell Signaling.
Ethics Statement
Neutrophils were isolated from human blood from healthy
volunteers with a written informed consent. All experiments were
approved by the INSERM (Institut National de la Sante ´e td e
Recherche Me ´dicale) institutional review board and ethics
committee. Data collection and analyses were performed anony-
mously.
All animal work was conducted according to relevant national
and international guidelines in accordance with the recommen-
dations of the Weatherall report. All animal experiments were
approved by the Committee on Animal Experimentation of
INSERM and performed in compliance with the care and use of
laboratory animals.
Human neutrophil preparation and measurement of ROS
production
Human neutrophils were isolated in LPS-free conditions by
means of one step purification on polymorphprep gradient dextran
sedimentation as previously described [18] . ROS production was
measured by luminol-amplified chemiluminescence method: cells
(5610
5) were suspended in 0.5 ml HBSS containing 10 mM
luminol preheated to 37uC in the thermostated chamber of the
luminometer (Berthold-Biolumat LB937). After a baseline reading,
cells were treated by punicic acid, TNFa then stimulated with
10
27 M fMLP and chemiluminescence was recorded.
Detection of Ser345 and p38MAPKinase phosphorylation
in neutrophils by a specific antibody
Neutrophils (1610
7 cells/ml) were incubated in the absence or
presence of different concentrations of punicic acid for 30 min,
then treated with TNFa (10 ng/ml) for 20 min. Cells were lysed
and proteins were denatured in Laemmli’s sample buffer [66]. The
samples were subjected to SDS-polyacrylamide gel electrophoresis
(PAGE) in 10% polyacrylamide gels, and Western-Blot using
standard techniques. Immunoblotting were performed with
primary rabbit polyclonal antibodies : anti-phospho-Ser345
antibody (1/10 000 dilution) or anti-p47phox antibody (1/5000
dilution) or anti-phospho p38MAPKinases (1/2000) then with
HRPO-labeled-goat anti-rabbit antibody (1/10 000). The reaction
was detected using ECL reagents.
Measurement of MPO release from human neutrophils
MPO release was performed by measuring MPO activity using
H2O2-dependent tetramethyl benzidine (TMB)-oxidation assay at
650 nm. Cells (5610
6) were suspended in 0.5 ml HBSS, preheated
to 37uC in the water bath, cells were treated with punicic acid,
TNFa, cytochalasin B then stimulated or not with 10
27 M fMLP.
Neutrophils were rapidly centrifuged and MPO activity was
measured in the supernatants. Total MPO activity was expressed
in mU/min relative to a standard curve established with known
quantities of triton X-100 treated neutrophils.
Animal experiments
Different groups of 10 rats (male Wistar 200 g, Elevage
Janvier, Le Genest-St-Isle, France) were used. Punicic acid in
PBS (400 mg/0.5 ml) or PBS alone (0.5 ml) or pomegranate seed
oil (0.5 ml) were orally administered once a day for 10 days
Figure 7. Punicic acid decreases TNBS induced MPO activity and
F2- isoprostanes production in rat colons. Rats were treated as
describedinFigure4and5.MPOactivity(A)wasdefinedasthatdegrading
1 mmol of hydrogen peroxide per g of tissue per minute. F2-isoprostane
levels (B) was measured as described in Materials and methods. Data are
expressed as mean+/2SEM of 6 rats in each group. (* p,0.05).
doi:10.1371/journal.pone.0006458.g007
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colitis, rats were anesthetized for 90–120 min, then they received
an intrarectal administration of TNBS (250 ml, 150 mg/Kg)
dissolved in a 1:1 mixture of 0.9% NaCl with 100% ethanol.
Control rats received a 1:1 mixture of 0.9% NaCl with 100%
ethanol or a saline solution using the same technique as described
previously (61). Animals were sacrificed 2 days after TNBS
administration. Macroscopic and histological evaluation of colitis
were made blindly by two investigators. The colon of each rat
was examined to evaluate macroscopic lesions according to the
Wallace criteria. The Wallace score rates macroscopic lesions on
a scale from 0 to 10 based on features reflecting inflammation
such as hyperemia, thickening of the bowel and extent of
ulceration. A colon specimen located 1 cm above the anus was
used for histological evaluation according to the Ameho criteria.
This grading is scaled from 0 to 6 and takes into account the
presence of erosion, ulceration or necrosis and the depth and
surface of lesions.
Confocal microscopy
Formalin-fixed, paraffin-embedded colon sections (5 mm) on
glass slides were deparaffiniz e di nt o l u e n ea n dr e h y d r a t e d
through graded alcohol solutions. After washing in PBS, the
tissues were permeabilized with 1% Triton-X/PBS/BSA for
10 min and blocked with goat serum (Dako A/S Denmark) for
1 hour. After washing, the tissues were incubated overnight at
4uC with rabbit anti-phospho-Ser345p47phox polyclonal anti-
body (1:1000), and mouse anti-gp91phox monoclonal antibody
(1:1000) diluted in 1% BSA/PBS. Following this incubation, the
tissues were washed four times in PBS and incubated with Alexa
Fluor 488-(green) conjugated goat anti-rabbit antibody (1:200)
diluted in 1% BSA/PBS and Alexa Fluor 568 (red) conjugated
goat anti mouse (1:200) for 1 h at room temperature in the dark.
After washing five times with PBS, cells were mounted using the
Prolong Gold antifade kit following the manufacturer’s
instruction. Stained cells were examined with a 63/1.4
numerical aperture objective under a Zeiss LSM510 confocal
microscope (Carl Zeiss, Heidelberg, Germany), and the images
were imported into an LSM image browser (Carl Zeiss) for
analysis.
Measurement of isoprostanes and MPO activity
F2-isoprostanes are produced by a non cyclooxygenase free
radical induced lipid peroxidation of membrane bound arachi-
donic acid. Mucosal F2-isoprostane concentrations were used as
indexes of markers of lipid peroxidation induced by oxidative
stress [45]. Total F2-isoprostane concentrations were determined
in colonic mucosa with a commercially available enzyme
immunoassay (EIA) kit (Cayman Chemical, An Abor,MI). Briefly,
approximately 30 mg of freshly thawed tissue were added to 10 vol
of chloroform-methanol (2/1, vol/vol) containing butylated
hydroxytoluene and flushed with a gentle stream of nitrogen.
The sample was vortexed and the lipid phase was extracted,
evaporated to dryness under a stream of nitrogen and resuspended
Figure 8. Effect of pomegranate seed oil on TNBS-induced colitis in rats. Photomicrographs (magnification640) were representative of H&E
stained slides of paraffin embedded colonic tissues recovered from (A) controls, (B) TNBS alone and (C) TNBS plus pomegranate seed oil. Histologic
and macroscopic lesions following TNBS treatment are represented by Wallace score (D) and Ameho score (E) score. The tissues are representative of
8 rats from each experimental group. Rats treated with oil show lower scores as compared to rats which received TNBS only. (* p,0.01).
doi:10.1371/journal.pone.0006458.g008
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affinity column containing anti F2-isoprostane monoclonal
antibody. F2-Isoprostanes were eluted off the column with pure
ethanol. The ethanolic phase was evaporated to dryness under a
stream of nitrogen, reconstituted in EIA buffer, and assayed
according to the manufacturer’s recommendations. Results are
expressed as pg isoprostane/mg proteins. MPO activity on the
homogenized colon tissue was measured using the same technique
as described above.
Statistical analysis
All results are expressed as means6standard error of the mean
(SEM). Significant differences were identified with Student’s t test;
p values of ,0.05 were considered significant.
Author Contributions
Conceived and designed the experiments: FD JEB. Performed the
experiments: TB HR PL JCM. Analyzed the data: TB MAGP JCM
JEB. Contributed reagents/materials/analysis tools: PL. Wrote the paper:
MAGP FD JEB.
References
1. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis.
Gastroenterology 115: 182–205.
2. Nathan C (2002) Points of control in inflammation. Nature 420: 846–852.
3. O’Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory
responses. Immunity 28: 477–487.
4. Nathan CF (1989) Respiratory burst in adherent human neutrophils: triggering
by colony-stimulating factors CSF-GM and CSF-G. Blood 73: 301–306.
5. Babior BM (2000) Phagocytes and oxidative stress. Am J Med 109: 33–44.
6. Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:
678–689.
7. Klebanoff SJ (2005) Myeloperoxidase: friend and foe. J Leukoc Biol 77:
598–625.
8. Segal AW (2005) How neutrophils kill microbes. Annu Rev Immunol 23:
197–223.
9. Babior BM (1984) Oxidants from phagocytes: agents of defense and destruction.
Blood 64: 959–966.
10. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Elbim C (2005) Phagocyte
NADPH oxidase: a multicomponent enzyme essential for host defenses. Arch
Immunol Ther Exp (Warsz) 53: 199–206.
11. Chanock SJ, el Benna J, Smith RM, Babior BM (1994) The respiratory burst
oxidase. J Biol Chem 269: 24519–24522.
12. Quinn MT, Gauss KA (2004) Structure and regulation of the neutrophil
respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc
Biol 76: 760–781.
13. Groemping Y, Rittinger K (2005) Activation and assembly of the NADPH
oxidase: a structural perspective. Biochem J 386: 401–416.
14. El Benna J, Faust LP, Babior BM (1994) The phosphorylation of the respiratory
burst oxidase component p47phox during neutrophil activation. Phosphoryla-
tion of sites recognized by protein kinase C and by proline-directed kinases. J Biol
Chem 269: 23431–23436.
15. El Benna J, Faust RP, Johnson JL, Babior BM (1996) Phosphorylation of the
respiratory burst oxidase subunit p47phox as determined by two-dimensional
phosphopeptide mapping. Phosphorylation by protein kinase C, protein kinase
A, and a mitogen-activated protein kinase. J Biol Chem 271: 6374–6378.
16. Faust LR, el Benna J, Babior BM, Chanock SJ (1995) The phosphorylation
targets of p47phox, a subunit of the respiratory burst oxidase. Functions of the
individual target serines as evaluated by site-directed mutagenesis. J Clin Invest
96: 1499–1505.
17. El-Benna J, Dang PM, Gougerot-Pocidalo MA (2008) Priming of the neutrophil
NADPH oxidase activation: role of p47phox phosphorylation and NOX2
mobilization to the plasma membrane. Semin Immunopathol 30: 279–289.
18. Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, et al. (2006) A specific
p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil
NADPH oxidase priming at inflammatory sites. J Clin Invest 116: 2033–2043.
19. DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella M, et al. (1998)
Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase
assembly. J Clin Invest 101: 455–463.
20. Ward RA, Nakamura M, McLeish KR (2000) Priming of the neutrophil
respiratory burst involves p38 mitogen-activated protein kinase-dependent
exocytosis of flavocytochrome b558-containing granules. J Biol Chem 275:
36713–36719.
21. Dang PM, Dewas C, Gaudry M, Fay M, Pedruzzi E, et al. (1999) Priming of
human neutrophil respiratory burst by granulocyte/macrophage colony-
stimulating factor (GM-CSF) involves partial phosphorylation of p47(phox).
J Biol Chem 274: 20704–20708.
22. Dewas C, Dang PM, Gougerot-Pocidalo MA, El-Benna J (2003) TNF-alpha
induces phosphorylation of p47(phox) in human neutrophils: partial phosphor-
ylation of p47phox is a common event of priming of human neutrophils by TNF-
alpha and granulocyte-macrophage colony-stimulating factor. J Immunol 171:
4392–4398.
23. Brown GE, Stewart MQ, Bissonnette SA, Elia AE, Wilker E, et al. (2004)
Distinct ligand-dependent roles for p38 MAPK in priming and activation of the
neutrophil NADPH oxidase. J Biol Chem 279: 27059–27068.
24. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429.
25. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A (2001) Neutrophil
transmigration in inflammatory bowel disease is associated with differential
expression of epithelial intercellular junction proteins. Am J Pathol 159:
2001–2009.
26. Naito Y, Takagi T, Yoshikawa T (2007) Molecular fingerprints of neutrophil-
dependent oxidative stress in inflammatory bowel disease. J Gastroenterol 42:
787–798.
27. Naito Y, Takagi T, Yoshikawa T (2007) Neutrophil-dependent oxidative stress
in ulcerative colitis. J Clin Biochem Nutr 41: 18–26.
28. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and
inflammatory diseases. Am J Clin Nutr 83: 1505S–1519S.
29. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, et al. (2006) Transgenic
mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl
Acad Sci U S A 103: 11276–11281.
30. Thompson PJ, Misso NL, Passarelli M, Phillips MJ (1991) The effect of
eicosapentaenoic acid consumption on human neutrophil chemiluminescence.
Lipids 26: 1223–1226.
31. Luostarinen R, Saldeen T (1996) Dietary fish oil decreases superoxide
generation by human neutrophils: relation to cyclooxygenase pathway and
lysosomal enzyme release. Prostaglandins Leukot Essent Fatty Acids 55:
167–172.
32. Kew S, Banerjee T, Minihane AM, Finnegan YE, Muggli R, et al. (2003) Lack
of effect of foods enriched with plant- or marine-derived n-3 fatty acids on
human immune function. Am J Clin Nutr 77: 1287–1295.
33. Bartelt S, Timm M, Damsgaard CT, Hansen EW, Hansen HS, et al. (2008) The
effect of dietary fish oil-supplementation to healthy young men on oxidative
burst measured by whole blood chemiluminescence. Br J Nutr 99: 1230–1238.
34. Kelley NS, Hubbard NE, Erickson KL (2007) Conjugated linoleic acid isomers
and cancer. J Nutr 137: 2599–2607.
35. Nagao K, Yanagita T (2005) Conjugated fatty acids in food and their health
benefits. J Biosci Bioeng 100: 152–157.
36. Hwang DM, Kundu JK, Shin JW, Lee JC, Lee HJ, et al. (2007) cis-9,trans-11-
conjugated linoleic acid down-regulates phorbol ester-induced NF-kappaB
activation and subsequent COX-2 expression in hairless mouse skin by targeting
IkappaB kinase and PI3K-Akt. Carcinogenesis 28: 363–371.
37. Tsuzuki T, Tokuyama Y, Igarashi M, Miyazawa T (2004) Tumor growth
suppression by alpha-eleostearic acid, a linolenic acid isomer with a conjugated
triene system, via lipid peroxidation. Carcinogenesis 25: 1417–1425.
38. Kim ND, Mehta R, Yu W, Neeman I, Livney T, et al. (2002) Chemopreventive
and adjuvant therapeutic potential of pomegranate (Punica granatum) for
human breast cancer. Breast Cancer Res Treat 71: 203–217.
39. Kohno H, Suzuki R, Yasui Y, Hosokawa M, Miyashita K, et al. (2004)
Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically
induced colon carcinogenesis in rats. Cancer Sci 95: 481–486.
40. Murakami A, Ishida H, Kobo K, Furukawa I, Ikeda Y, et al. (2005) Suppressive
effects of Okinawan food items on free radical generation from stimulated
leukocytes and identification of some active constituents: implications for the
prevention of inflammation-associated carcinogenesis. Asian Pac J Cancer Prev
6: 437–448.
41. Tatsukawa M, Sawayama Y, Maeda N, Okada K, Furusyo N, et al. (2004)
Carotid atherosclerosis and cardiovascular risk factors: a comparison of residents
of a rural area of Okinawa with residents of a typical suburban area of Fukuoka,
Japan. Atherosclerosis 172: 337–343.
42. Yonemaru M, Stephens KE, Ishizaka A, Zheng H, Hogue RS, et al. (1989)
Effects of tumor necrosis factor on PMN chemotaxis, chemiluminescence, and
elastase activity. J Lab Clin Med 114: 674–681.
43. Ginzberg HH, Cherapanov V, Dong Q, Cantin A, McCulloch CA, et al. (2001)
Neutrophil-mediated epithelial injury during transmigration: role of elastase.
Am J Physiol Gastrointest Liver Physiol 281: G705–717.
44. Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of
inflammation. Annu Rev Immunol 20: 495–549.
45. Lawson JA, Rokach J, FitzGerald GA (1999) Isoprostanes: formation, analysis
and use as indices of lipid peroxidation in vivo. J Biol Chem 274: 24441–24444.
46. Yamasaki M, Kitagawa T, Koyanagi N, Chujo H, Maeda H, et al. (2006)
Dietary effect of pomegranate seed oil on immune function and lipid metabolism
in mice. Nutrition 22: 54–59.
47. Papadakis KA, Targan SR (2000) Tumor necrosis factor: biology and
therapeutic inhibitors. Gastroenterology 119: 1148–1157.
Punicic Acid and Inflammation
PLoS ONE | www.plosone.org 11 July 2009 | Volume 4 | Issue 7 | e645848. Feldmann M (2008) Many cytokines are very useful therapeutic targets in
disease. J Clin Invest 118: 3533–3536.
49. Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL Jr, et al. (2008)
Priming of neutrophil oxidative burst in diabetes requires preassembly of the
NADPH oxidase. J Leukoc Biol 84: 292–301.
50. D’Odorico A, D’Inca R, Mestriner C, Di Leo V, Ferronato A, et al. (2000)
Influence of disease site and activity on peripheral neutrophil function in
inflammatory bowel disease. Dig Dis Sci 45: 1594–1600.
51. Hatanaka E, Levada-Pires AC, Pithon-Curi TC, Curi R (2006) Systematic study
on ROS production induced by oleic, linoleic, and gamma-linolenic acids in
human and rat neutrophils. Free Radic Biol Med 41: 1124–1132.
52. Thies F, Miles EA, Nebe-von-Caron G, Powell JR, Hurst TL, et al. (2001)
Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated
fatty acids on blood inflammatory cell populations and functions and on plasma
soluble adhesion molecules in healthy adults. Lipids 36: 1183–1193.
53. Lewis RA, Austen KF, Soberman RJ (1990) Leukotrienes and other products of
the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in
human diseases. N Engl J Med 323: 645–655.
54. Tilley SL, Coffman TM, Koller BH (2001) Mixed messages: modulation of
inflammation and immune responses by prostaglandins and thromboxanes.
J Clin Invest 108: 15–23.
55. Harbige LS (2003) Fatty acids, the immune response, and autoimmunity: a
question of n-6 essentiality and the balance between n-6 and n-3. Lipids 38:
323–341.
56. Hardy SJ, Ferrante A, Poulos A, Robinson BS, Johnson DW, et al. (1994) Effect
of exogenous fatty acids with greater than 22 carbon atoms (very long chain fatty
acids) on superoxide production by human neutrophils. J Immunol 153:
1754–1761.
57. Li Y, Ferrante A, Poulos A, Harvey DP (1996) Neutrophil oxygen radical
generation. Synergistic responses to tumor necrosis factor and mono/
polyunsaturated fatty acids. J Clin Invest 97: 1605–1609.
58. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al.
(2004) Activation of PPAR gamma and delta by conjugated linoleic acid
mediates protection from experimental inflammatory bowel disease. Gastroen-
terology 127: 777–791.
59. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, et al. (2005) Resolvin
E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid,
protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl
Acad Sci U S A 102: 7671–7676.
60. Barrett EG, Johnston C, Oberdorster G, Finkelstein JN (1999) Silica-induced
chemokine expression in alveolar type II cells is mediated by TNF-alpha-
induced oxidant stress. Am J Physiol 276: L979–988.
61. Handa O, Naito Y, Takagi T, Shimozawa M, Kokura S, et al. (2004) Tumor
necrosis factor-alpha-induced cytokine-induced neutrophil chemoattractant-1
(CINC-1) production by rat gastric epithelial cells: role of reactive oxygen species
and nuclear factor-kappaB. J Pharmacol Exp Ther 309: 670–676.
62. Hashimoto S, Gon Y, Matsumoto K, Takeshita I, Horie T (2001) N-
acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and
p38 MAP kinase-mediated IL-8 production by human pulmonary vascular
endothelial cells. Br J Pharmacol 132: 270–276.
63. Arao K, Wang YM, Inoue N, Hirata J, Cha JY, Nagao K, Yanagita T (2004)
Dietary effect of pomegranate seed oil rich in 9cis, 11trans, 13cis conjugated
linolenic acid on lipid metabolism in obese, hyperlipidemic OLETF rats. Lipids
Health Dis 3: 24–30.
64. Tsuzuki T, Kawakami Y, Abe R, Nakagawa K, Koba K, Imamura J, Iwata T,
Ikeda I, Miyazawa T (2006) Conjugated linolenic acid is slowly absorbed in rat
intestine, but quickly converted to conjugated linoleic acid. J Nutr 136:
2153–159.
65. MacLean CH, Mojica WA, Morton SC, Pencharz J, Hasenfeld Garland R, et al.
(2004) Effects of omega-3 fatty acids on lipids and glycemic control in type II
diabetes and the metabolic syndrome and on inflammatory bowel disease,
rheumatoid arthritis, renal disease, systemic lupus erythematosus, and
osteoporosis. Evid Rep Technol Assess (Summ). pp 1–4.
66. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227: 680–685.
Punicic Acid and Inflammation
PLoS ONE | www.plosone.org 12 July 2009 | Volume 4 | Issue 7 | e6458